Long-Term Study of IGIV, 10% in Alzheimer´s Disease

Status Terminated

Clinical Trial Summary

The purpose of this long-term study is to provide additional evidence of safety and efficacy of IGIV, 10% treatment in participants with Alzheimer´s Disease who have completed the Phase 3 Baxter precursor study 160701. All participants will receive IGIV, 10% at either 0.2 g/kg or 0.4 g/kg body weight depending on their treatment assignment in Baxter study 160701. Participants and investigators will be blinded to dose unless otherwise notified by the sponsor.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01736579
Study type	Interventional
Source	Takeda
Contact
Status	Terminated
Phase	Phase 3
Start date	November 29, 2012
Completion date	June 4, 2013

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02245737` - An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease	Phase 2/Phase 3
Completed	`NCT02360527` - Retinal Neurodegeneration in Type 2 Diabetes as Biomarker for Alzheimer´s Disease	N/A
Completed	`NCT01225809` - AD01 Follow up Extension Visit	N/A
Terminated	`NCT01117948` - Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.	Phase 2
Completed	`NCT02501876` - Type 2 Diabetes Mellitus as Catalyst for Alzheimer's Disease	N/A
Active, not recruiting	`NCT01695889` - Is There a Relationship Between Previous Exposure to General Anesthesia and the Development of Alzheimer´s Disease?	N/A
Completed	`NCT00608946` - Treatment With Copper in Patients With Mild Alzheimer´s Dementia	Phase 2
Terminated	`NCT02008513` - Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006	Phase 2
Completed	`NCT02224326` - Vagus Somatosensory Evoked Potentials and Near-infrared Spectroscopy in the Early Diagnosis of Dementia
Terminated	`NCT01125683` - To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease	Phase 2
Terminated	`NCT01357629` - Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease	N/A
Terminated	`NCT01524887` - Phase 3 IGIV, 10% in Alzheimer´s Disease	Phase 3
Completed	`NCT00692705` - Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid	Phase 1
Active, not recruiting	`NCT02623764` - EEG-cholinergic Index and Clinical Response to Treatment With Cholinesterase Inhibitors
Completed	`NCT00948259` - Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease	Phase 1/Phase 2
Completed	`NCT00818662` - A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease	Phase 3